The combination of Hsp90 inhibitor 17AAG and heavy‐ion irradiation provides effective tumor control in human lung cancer cells

Cancer Medicine

Hirokazu Hirakawa²  Hiroshi Fujisawa²  Aya Masaoka²  Miho Noguchi¹  Ryoichi Hirayama²  Momoko Takahashi³  Akira Fujimori² 

[1] Advanced Science Research Center, Japan Atomic Energy Agency, Tokai-mura, Japan;International Open Laboratory and Research Center for Charged Particle Therapy/Research Center for Radiation Protection, National Institute of Radiological Sciences, Chiba, Japan;Translational Research Center, Fukushima Medical University, Fukushima City, Japan

关键词: 17AAG;    DNA repair;    heavy ions;    Hsp90 inhibitor;    lung cancer;   

DOI  :  10.1002/cam4.377

来源: Wiley

【 摘 要 】

Abstract

Hsp90 inhibitors have become well-studied antitumor agents for their selective property against tumors versus normal cells. The combined treatment of Hsp90 inhibitor and conventional photon radiation also showed more effective tumor growth delay than radiation alone. However, little is known regarding the combined treatment of Hsp90 inhibitor and heavy-ion irradiation. In this study, SQ5 human lung tumor cells were used in vitro for clonogenic cell survival and in vivo for tumor growth delay measurement using a mouse xenograft model after 17-allylamino-17-demethoxygeldanamycin (17AAG) pretreatment and carbon ion irradiation. Repair of DNA double strand breaks (DSBs) was also assessed along with expressions of DSB repair-related proteins. Cell cycle analysis after the combined treatment was also performed. The combined treatment of 17AAG and carbon ions revealed a promising treatment option in both in vitro and in vivo studies. One likely cause of this effectiveness was shown to be the inhibition of homologous recombination repair by 17AAG. The more intensified G2 cell cycle delay was also associated with the combined treatment when compared with carbon ion treatment alone. Our findings indicate that the combination of Hsp90 inhibition and heavy-ion irradiation provides a new effective therapeutic alternative for treatment of solid tumors.

【 授权许可】

CC BY   
© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.